Opinion|Videos|July 12, 2024 (Updated: July 12, 2024)
ADCs Targeting GI Cancers
Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please review the data for T-DM1 for:
- HER2+ advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocaricoma: GATSBY; Shah-Gastric Cancer_2019: Biomarker analysis of GATSBY
- T-DM1 + Pertuzumab for HER2-amplified colorectal cancer: HERACLES-B trial
- Please review the data for T-DXd for:
- HER2+ gastric or GEJ: DESTINY-Gastric01; Shitara_Nature Med_2024: Biomarker Analysis of DESTINY-Gastric01 and DESTINY-Gastric02
- Unresectable or metastatic HER2+ CRC: DESTINY-CRC01 1. DESTINY-CRC02 – Raghav_ASCO 2023
- HER2+ and HER2-low GC: DESTINY-Gastric03 Janjigian ASCO 2024
- Retrospective Cohort Study EN-DEAVOR: Nakanishi ASCO 2024
- What is the potential for HER2-targeting ADCs in other GI cancers?
- Biliary Tract Cancers, Pancreatic
- PanTumor02: Meric-Bernstam_J Clin Oncol_2024; a. BTC and PC Cohort Outcomes: Oh ASCO 2024 #4090
- HERB trial (BTC): Ohba_ASCO2022
- Biliary Tract Cancers, Pancreatic
- Where do HER2-directed ADCs fit into the treatment armamentarium for GI cancers?
- Is there an unmet need ADCs could help fill?
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Tenumomeran/raplemomeran plus pembrolizumab missed the PFS end point in HPV16-positive HNSCC.
Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.
AI-assisted scoping review of code sharing in clinical prediction model research
Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
Roswell Park Comprehensive Cancer Center has earned national recognition in 2026 from the American Medical Association as a Joy in Medicine organization.
Advertisement
Advertisement